Shyam A Patel, Elisa Bello, Andrew Wilks, Jonathan M Gerber, Narayanan Sadagopan, Jan Cerny
Numerous recent advances have been made in therapeutic approaches toward acute myeloid leukemia (AML). Since 2017, we have seen eleven novel Food & Drug Administration (FDA)-approved medications for AML, all of which extend beyond the classical cytarabine-based cytostatic chemotherapy. In the recent two decades, the role of immune surveillance in AML has been intensively investigated. The power of one's own innate and adaptive immunity has been harnessed pharmacologically toward the goal of clearance of AML cells...
September 14, 2023: Leukemia Research
Gunnar Larfors, Daniel Moreno Berggren, Hege Garelius, Lars Nilsson, Bengt Rasmussen, Eva Hellström-Lindberg, Elisabeth Ejerblad
Comorbidities influence the mortality in patients with myelodysplastic syndromes, and a growing body of evidence suggest that comorbidity history should be used in addition to established prognostic indices. A comorbidity index specific for MDS, the MDS-CI, was introduced a decade ago. In this study we aim to construct an MDS-CI version based on diagnoses from register data only, to expand its use beyond the clinical setting to retrospective and register based studies. We further test this version on a Swedish population-based MDS cohort of 2947 patients, and compare its prognostic accuracy to that of Charlson Comorbidity Index...
September 7, 2023: Leukemia Research
Ismail Elbaz Younes, Lee Syler, Amira Hamed
No abstract text is available yet for this article.
September 4, 2023: Leukemia Research
Sumukh Arun Kumar, Jenny Gao, Shyam A Patel
Mantle cell lymphoma (MCL) is a heterogeneous subtype of non-Hodgkin lymphoma that has been historically associated with poor 5-year overall survival rates, especially for aggressive variants. Traditional cytotoxic chemotherapy had been a mainstay of therapy for relapsed/refractory (R/R) MCL for many years until the advent of molecularly targeted therapies and cell-based approaches. However, a significant concern is the lack of definitive consensus guidelines for management of R/R MCL. The managerial conundrum partly stems from the absence of head-to-head comparisons of novel therapies, with conclusions drawn from cross-trial comparisons...
September 1, 2023: Leukemia Research
Davidson Zhao, Qianghua Zhou, Mojgan Zarif, Entsar Eladl, Cuihong Wei, Eshetu G Atenafu, Andre Schuh, Anne Tierens, Yu Wing Tony Yeung, Mark D Minden, Hong Chang
AML with CEBPA mutation and AML with in-frame bZIP CEBPA mutations define favorable-risk disease entities in the proposed 5th edition of the World Health Organization Classification (WHO-HAEM5) and the International Consensus Classification (ICC), respectively. However, the impact of these new classifications on clinical practice remains unclear. We sought to assess the differences between the ICC and WHO-HAEM5 for AML with CEBPA mutation. 741 AML patients were retrospectively analyzed. Cox proportional-hazard regression was used to identify factors predictive of outcome...
August 29, 2023: Leukemia Research
Stefan Nagel, Anja Fischer, Susanne Bens, Vivien Hauer, Claudia Pommerenke, Cord C Uphoff, Margarete Zaborski, Reiner Siebert, Hilmar Quentmeier
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a mature, CD30-positive T-cell lymphoma lacking expression of the anaplastic lymphoma kinase (ALK). In contrast to ALK-positive ALCL, BIA-ALCL cells express cyclin D2 (CCND2) which controls cyclin dependent kinases 4 and 6 (CDK4/6). DNA methylation and expression analyses performed with cell lines and primary cells suggest that the expression of CCND2 in BIA-ALCL cell lines conforms to the physiological status of differentiated T-cells, and that it is not the consequence of genomic alterations as observed in other hematopoietic tumors...
August 27, 2023: Leukemia Research
Fatima M Khadadah, Sonia Cerquozzi, Harold J Olney, Christina Fraga, Jill Dudebout, Anargyros Xenocostas, Nicholas Finn, Vincent Ethier, M Lynn Savoie, Lambert Busque, Kareem Jamani, Philip Kuruvilla, Carolyn Faught, Brian Leber, Rayan Kaedbey, Sarit E Assouline, Dennis Kim
BACKGROUND: Asciminib is a novel drug specifically targeting ABL myristoyl pocket in the ABL1 protein. METHODS: Forty one patients with chronic myeloid leukemia treated with asciminib from 2018 to 2022 were reviewed and analyzed for the efficacy and tolerability of asciminib using real-world experience data. RESULTS: The median age was 60 years (range 17-90) with a past history of a cardiovascular event in 21 patients (51%). Patients were pretreated with a median of 3 previous tyrosine kinase inhibitors (range 1-5)...
August 22, 2023: Leukemia Research
Fernando De la Garza-Salazar, Perla Rocío Colunga-Pedraza, David Gómez-Almaguer, Valeria Abigail García-Zárate, Andrés Gómez-De León
Data concerning venetoclax and azacitidine (Ven/Aza) as first-line therapy for newly diagnosed acute myeloid leukemia (ND-AML) in candidates for intensive chemotherapy are limited, and outpatient induction regimens in ND-AML have been poorly explored. The enzyme CYP3A4 metabolizes Venetoclax. Conversely, itraconazole is a strong CYP3A4 inhibitor; thus, it produces a 75 % reduction in the dose and cost of venetoclax. This phase 2 trial assessed the feasibility, safety, and efficacy of outpatient induction with venetoclax 100 mg daily from days 1-21, itraconazole 100 mg twice daily from days 1-21, and azacytidine 100 mg subcutaneously, once daily from days 1-7...
August 22, 2023: Leukemia Research
Carolyn Owen, Sarah Eisinga, Versha Banerji, Nathalie Johnson, Alina S Gerrie, Andrew Aw, Christine Chen, Sue Robinson
Following the recent publication of Canadian evidence-based guidelines for frontline treatment of chronic lymphocytic leukemia (CLL), the same group of clinicians developed guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few years, with many novel therapeutics available to hematologists across the country. These guidelines aim to standardize the management of CLL in the relapsed/refractory setting, using the best evidence currently available...
August 19, 2023: Leukemia Research
Ian M Bouligny, Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A Wages, Steven Grant, Keri R Maher
No abstract text is available yet for this article.
August 16, 2023: Leukemia Research
Zhen-Yu Zhao, Nan Tang, Li-Er Lin
BACKGROUND: The purpose of this report is to enhance our scientific understanding of the clinicopathologic features of chronic myeloid leukemia (CML) with the e12a3 transcript and to provide insights into potential treatment options for this rare subtype of CML. CASE SUMMARY: We present the case of a 21-year-old Chinese male patient who was diagnosed with chronic myeloid leukemia (CML) with the e12a3 transcript. Biopsy of his left iliac soft tissue mass indicated that he was in the blast crisis phase of CML...
August 8, 2023: Leukemia Research
Shinichi Kako, Shun-Ichi Kimura, Hidenori Wada, Yusuke Komiya, Hideki Nakasone, Masatoshi Sakurai, Jun Kato, Masatsugu Tanaka, Eriko Fujii, Takayoshi Tachibana, Wataru Yamamoto, Maki Hagihara, Reiko Watanabe, Akira Yokota, Hirofumi Nakano, Takehiko Mori, Chiaki Nakaseko, Heiwa Kanamori, Shinichiro Okamoto, Yoshinobu Kanda
The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We performed a prospective observational study in which 110 patients with MDS who were decided to undergo HSCT were enrolled. Among these 110 patients, 77 patients were enrolled in this study within 1 month from the decision for HSCT. Among these 77 patients, 13 patients had a human leukocyte antigen (HLA)-matched sibling, 54 patients started an unrelated donor search, and the other 10 patients directly selected cord blood (CB) at the decision for HSCT, and 13 (100%), 38 (70...
August 7, 2023: Leukemia Research
A Sherban, D Fredman, S Shimony, M Yeshurun, P Raanani, M Stahi, A Gafter-Gvili, O Wolach
Venetoclax (VEN) in combination with intensive chemotherapy (IC) is increasingly used to treat patients with high-risk acute myeloid leukemia (AML). We conducted a systematic review to assess the safety and efficacy outcomes of FLAG-IDA in combination with VEN. The primary safety outcome was infection rate; the primary efficacy outcome was response to treatment (composite complete remission (CRc) and overall response rate (ORR). Risk of bias was assessed according to the ROBINS-I tool. Six studies including 221 patients with newly-diagnosed (ND AML (n = 120)) and R/R AML (n = 101) disease, were included in this systematic review...
August 4, 2023: Leukemia Research
Urmimala Bhattacharjee, Aditya Jandial, Charanpreet Singh, K S Lekshmon, Kundan Mishra, Rajeev Sandal, Ram Nampoothiri, Shano Naseem, Vanita Suri, Arihant Jain, Deepesh P Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
PURPOSE: Despite the general recommendation to avoid Tyrosine Kinase Inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) during pregnancy, unplanned pregnancies still occur, particularly among female patients residing in low- and middle-income countries (LMICs). We aimed to investigate the outcomes of pregnancy, foetal development, and disease progression among female CML patients in chronic phase (CML-CP) undergoing TKI therapy who encountered unplanned pregnancies in a tertiary care hospital in northern India...
August 2, 2023: Leukemia Research
Daniel J Chandra, Curtis A Lachowiez
No abstract text is available yet for this article.
July 29, 2023: Leukemia Research
Muhlis Cem Ar, Riad El Fakih, Saule Gabbassova, Ahmad Alhuraiji, Fady Nasr, Ahmad Alsaeed, Nilgun Sayinalp, Mahmoud Marashi
Secondary immunodeficiency (SID) can occur as a result of multiple factors, including hematological malignancies, hematopoietic stem cell transplantation (HSCT), immunosuppressive treatment, biologics, and anti-inflammatory drugs. SID includes disorders resulting from impairment of both cellular and humoral immunity. This review focuses on the current risk factors, implications, and challenges in managing SID patients with impaired humoral immunity, which includes quantitative (hypogammaglobulinemia) and/or functional antibody and B-cell deficiencies specifically related to hematological malignancies and post-HSCT...
July 27, 2023: Leukemia Research
Christian K Hirt, Nandan Padmanabha, Phillip D Michaels
No abstract text is available yet for this article.
July 20, 2023: Leukemia Research
Mrinal M Patnaik
No abstract text is available yet for this article.
July 18, 2023: Leukemia Research
Syed J Mehdi, Kalyan Ghatak, Wen Ling, Sarah K Johnson, Joshua Epstein, Intawat Nookaew, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Shmuel Yaccoby
Bone marrow mesenchymal stem cells (MSCs) may have contrasting impacts on the progression of multiple myeloma (MM). Priming normal MSCs, by culturing them with MM cells, mimics the MSC-induced MM growth. We studied the contrasting effects of conditioned medium (CM) from unprimed or primed MSCs on growth of MM cells from newly diagnosed cases. We elucidated potential molecular pathways using global gene expression profiling and focused on the role of the mTOR2 component, RICTOR, as a novel mediator of dormancy in MM...
July 14, 2023: Leukemia Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.